Resignation of CEO and Managing Director
Filed with ASX · · 2 pages · English
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Clinical milestones for 2024 & 2023 successes highlighted
- Half Yearly Report and Accounts
- 1st patient treated in ADVENT-AML Phase 1b clinical trial
- Placement of Entitlement Offer Shortfall
- ADVENT-AML Phase 1B clinical trial open to enrolment
Later from Chimeric Therapeutics
- CHM CDH17 Phase 1/2 clinical trial approved for initiation
- Chimeric opens CHM CDH17 Phase 1/2 trial
- Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
- First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
- First patient dosed in Phase 1/2 trial of CHM CDH17
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics